Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Shares Purchased by Benjamin Edwards Inc.

Benjamin Edwards Inc. lifted its holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 13,196.3% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 162,481 shares of the company's stock after acquiring an additional 161,259 shares during the quarter. Benjamin Edwards Inc. owned 0.06% of Recursion Pharmaceuticals worth $1,071,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in RXRX. Axxcess Wealth Management LLC boosted its position in Recursion Pharmaceuticals by 4.3% in the 3rd quarter. Axxcess Wealth Management LLC now owns 43,884 shares of the company's stock worth $289,000 after purchasing an additional 1,795 shares in the last quarter. Green Alpha Advisors LLC boosted its holdings in Recursion Pharmaceuticals by 2.9% during the third quarter. Green Alpha Advisors LLC now owns 64,799 shares of the company's stock worth $427,000 after buying an additional 1,800 shares in the last quarter. Interchange Capital Partners LLC grew its position in Recursion Pharmaceuticals by 7.3% during the second quarter. Interchange Capital Partners LLC now owns 34,580 shares of the company's stock valued at $268,000 after buying an additional 2,349 shares during the period. Amalgamated Bank increased its holdings in Recursion Pharmaceuticals by 52.4% in the second quarter. Amalgamated Bank now owns 7,152 shares of the company's stock valued at $54,000 after buying an additional 2,459 shares in the last quarter. Finally, Victory Capital Management Inc. raised its position in shares of Recursion Pharmaceuticals by 13.5% in the second quarter. Victory Capital Management Inc. now owns 21,891 shares of the company's stock worth $164,000 after acquiring an additional 2,598 shares during the period. Hedge funds and other institutional investors own 89.06% of the company's stock.

Analysts Set New Price Targets

A number of research firms have recently commented on RXRX. Needham & Company LLC restated a "buy" rating and set a $11.00 target price on shares of Recursion Pharmaceuticals in a research report on Wednesday, November 20th. Jefferies Financial Group reduced their target price on Recursion Pharmaceuticals from $8.00 to $6.00 and set a "hold" rating for the company in a research note on Tuesday, September 3rd. Finally, Leerink Partners dropped their price target on shares of Recursion Pharmaceuticals from $9.00 to $8.00 and set a "market perform" rating on the stock in a research note on Tuesday, September 3rd. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $9.25.

Insider Activity

In related news, COO Tina Marriott sold 6,000 shares of the firm's stock in a transaction dated Thursday, September 26th. The shares were sold at an average price of $7.00, for a total value of $42,000.00. Following the completion of the sale, the chief operating officer now owns 521,138 shares in the company, valued at $3,647,966. This trade represents a 1.14 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Michael Secora sold 15,000 shares of the company's stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $6.17, for a total transaction of $92,550.00. Following the transaction, the chief financial officer now owns 1,377,756 shares in the company, valued at $8,500,754.52. The trade was a 1.08 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 134,235 shares of company stock valued at $895,538 in the last three months. 15.75% of the stock is currently owned by company insiders.

Recursion Pharmaceuticals Price Performance

Shares of NASDAQ RXRX traded up $1.42 during midday trading on Friday, hitting $8.01. The stock had a trading volume of 30,761,670 shares, compared to its average volume of 10,777,311. Recursion Pharmaceuticals, Inc. has a 1 year low of $5.60 and a 1 year high of $15.74. The company has a market capitalization of $2.30 billion, a PE ratio of -5.24 and a beta of 0.85. The company has a quick ratio of 4.35, a current ratio of 4.35 and a debt-to-equity ratio of 0.04. The stock has a 50 day simple moving average of $6.61 and a 200-day simple moving average of $7.34.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.01). Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The firm had revenue of $26.08 million for the quarter, compared to analysts' expectations of $12.62 million. During the same period in the prior year, the company earned ($0.43) earnings per share. The company's revenue for the quarter was up 147.6% on a year-over-year basis. On average, sell-side analysts expect that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current fiscal year.

Recursion Pharmaceuticals Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.